Protective Effects of Ejiao on Chronic Obstructive Pulmonary Disease in Mice via Modulation of the ER/AKT/NF-κB Pathway

Abstract

Background and objectives: Chronic obstructive pulmonary disease (COPD) is an irreversible inflammatory lung disease. Studies have shown that macrophages and estrogen receptors play a pivotal regulatory role in the development of COPD. Ejiao (Colla Corii Asini, CCA, or donkey-hide gelatin), a traditional Chinese medicine, has anti-inflammatory and lung function-protective effects, but its specific mechanism in COPD remains unclear. This study aimed to explore the immunomodulatory effects of Ejiao on COPD, focusing on its impact on inflammatory pathways and macrophages.

Methods: This study is the first to apply a network pharmacology approach to explore the potential mechanisms underlying Ejiao’s therapeutic effects on COPD. We collected the peptides and chemical components of Ejiao and used the STRING database to screen for COPD-related targets of Ejiao components, constructing a drug-molecular network. Additionally, we established cigarette smoke extract (CSE) and lipopolysaccharide-induced cell injury models and treated them with Ejiao-containing serum. Western blot (WB) analysis was used to detect the expression of related proteins, enabling a preliminary exploration of Ejiao’s effects and regulatory mechanisms. In further experiments, a mouse COPD model was established, and eight weeks of Ejiao intervention were conducted. We assessed lung function, pathological changes in lung tissue, monitored cytokine levels in serum and bronchoalveolar lavage fluid, performed flow cytometry to evaluate abdominal macrophage levels, and conducted WB to analyze protein expression, providing an in-depth study of Ejiao’s regulatory effects on the mouse COPD model.

Results: The findings from the network pharmacology analysis suggest a potential regulatory role of the estrogen receptor pathway in COPD. CSE stimulation of RAW264.7 cells resulted in elevated tumor necrosis factor-α levels, decreased interleukin-10 levels, reduced expression of estrogen receptors (ERs) α and β, decreased inhibitor of NF-κB levels, and increased p-AKT levels. Following Ejiao intervention, interleukin-10, ERα+β, and inhibitor of NF-κB levels increased, while p-AKT levels decreased. Ejiao significantly improved lung function in CSE/lipopolysaccharide-induced COPD mice, reduced the number of macrophages, lowered the levels of inflammatory factors in bronchoalveolar lavage fluid, and increased estradiol levels in serum. WB results indicated that Ejiao may ameliorate lung injury in COPD by modulating the ER/AKT/NF-κB pathway.

Conclusions: The results suggest that Ejiao may improve lung injury and inflammation in CSE/ lipopolysaccharide-induced COPD by regulating the ER/AKT/NF-κB pathway.

Keywords

Chronic obstructive pulmonary disease / Estrogen receptors / Ejiao / Network pharmacology / AKT / NF-κB

References

[1] Upadhyay P, Wu CW, Pham A, Zeki AA, Royer CM, Kodavanti UP, et al. Animal models and mechanisms of tobacco smoke-induced chronic obstructive pulmonary disease (COPD). J Toxicol Environ Health B Crit Rev 2023; 26(5):275-305. doi:10.1080/10937404.2023.2208886, PMID:37183431.

[2] Uwagboe I, Adcock IM, Lo Bello F, Caramori G, Mumby S. New drugs under development for COPD. Minerva Med 2022; 113(3):471-496. doi:10.23736/S0026-4806.22.08024-7, PMID:35142480.

[3] Liu D, Xu W, Tang Y, Cao J, Chen R, Wu D, et al. Nebulization of risedronate alleviates airway obstruction and inflammation of chronic obstructive pulmonary diseases via suppressing prenylation-dependent RAS/ERK/NF-κB and RhoA/ROCK1/MLCP signaling. Respir Res 2022; 23(1):380. doi:10.1186/s12931-022-02274-5, PMID:36575527.

[4] Saito T, Fujino N, Kyogoku Y, Yamada M, Okutomo K, Ono Y, et al. Identification of Siglec-1-negative alveolar macrophages with proinflammatory phenotypes in chronic obstructive pulmonary disease. Am J Physiol Lung Cell Mol Physiol 2024; 326(6):L672-L686. doi:10.1152/ ajplung.00303.2023, PMID:38530936.

[5] Chakinala RC, Khatri A, Gupta K, Koike K, Epelbaum O. Sphingolipids in COPD. Eur Respir Rev 2019; 28(154):190047. doi: 10.1183/16000617.0047-2019, PMID:31694841.

[6] Zhao Z, Tong Y, Kang Y, Qiu Z, Li Q, Xu C, et al. Sodium butyrate (SB) ameliorated inflammation of COPD induced by cigarette smoke through activating the GPR43 to inhibit NF-κB/MAPKs signaling pathways. Mol Immunol 2023; 163:224-234. doi:10.1016/j. molimm.2023.10.007, PMID:37864932.

[7] Liu Y, Kong H, Cai H, Chen G, Chen H, Ruan W. Progression of the PI3K/ Akt signaling pathway in chronic obstructive pulmonary disease. Front Pharmacol 2023;14:1238782. doi:10.3389/fphar.2023.1238782, PMID:37799975.

[8] Guo Q, Jin Y, Chen X, Ye X, Shen X, Lin M, et al. NF-κB in biology and targeted therapy: new insights and translational implications. Signal Transduct Target Ther 2024; 9(1):53. doi:10.1038/s41392-024-01757- 9, PMID:38433280.

[9] Liang C, Chung HF, Dobson A, Sandin S, Weiderpass E, Mishra GD. Female reproductive histories and the risk of chronic obstructive pulmonary disease. Thorax 2024; 79(6):508-514. doi:10.1136/thorax-2023-220388, PMID:38350732.

[10] Xia W, Pan Z, Zhang H, Zhou Q, Liu Y. ERRα protects against sepsis-induced acute lung injury in rats. Mol Med 2023; 29(1):76. doi:10.1186/ s10020-023-00670-1, PMID:37340376.

[11] Lou Y, Fu Z, Tian Y, Hu M, Wang Q, Zhou Y, et al. Estrogen-sensitive activation of SGK1 induces M2 macrophages with anti-inflammatory properties and a Th2 response at the maternal-fetal interface. Reprod Biol Endocrinol 2023; 21(1):50. doi:10.1186/s12958-023-01102- 9, PMID:37226177.

[12] Chen P, Li B, Ou-Yang L. Role of estrogen receptors in health and disease. Front Endocrinol (Lausanne) 2022;13:839005. doi:10.3389/ fendo.2022.839005, PMID:36060947.

[13] Browne IM, André F, Chandarlapaty S, Carey LA, Turner NC. Optimal targeting of PI3K-AKT and mTOR in advanced oestrogen receptor- positive breast cancer. Lancet Oncol 2024;25(4):e139-e151. doi:10.1016/S1470-2045(23)00676-9, PMID:38547898.

[14] Li Z, Chen BF, Huang JM, Huang JK, Huang Q, TAN JB. Effects of gelatina nigra on cytoimmunity and humoral immunity function in mice. Chin J Health Lab Technol 2008; 18(7):1426-1427+1437.

[15] You Y, Wang K, Miao M, Zhang Y, Yuan H. Application of Ejiao(Asini Corii Colla) in Shennong’s Classic of Materia Medica and Classic Formulas. Journal of Shandong University of Traditional Chinese Medicine 2024; 48(6):679-684. doi:10.16294/j.cnki.1007-659x.2024.06.007.

[16] Qu YX, Fu YJ. Advances in Chemical Constituents, Quality Control and Pharmacological Effects of Asini corii colla. Special Wild Economic Animal and Plant Research 2023; 45(3):136-143. doi:10.16720/j.cnki. tcyj.2023.090.

[17] Zhao FD, Dong JC, Cui Y, Xie JY, Wu SM. The Effect of Ejiao on Airway Inflammation and Th1/Th2 Cytokines in Serum of Asthmatic Rats. Chin J Exp Tradit Med Formulae 2006; 12(6):59-61. doi:10.13422/j. cnki.syfjx.2006.06.022.

[18] Yue Q, Zhang W, Lin S, Zheng T, Hou Y, Zhang Y, et al. Ejiao ameliorates lipopolysaccharide-induced pulmonary inflammation via inhibition of NFκB regulating NLRP3 inflammasome and mitochondrial ROS. Biomed Pharmacother 2022;152:113275. doi:10.1016/j. biopha.2022.113275, PMID:35714510.

[19] Zhang PP, Ling YH, Yan XD, Wei JF, Jin HT, Wang AP. Protective effects of Colla Corii Asini on artificial fine particulate matter-induced respiratory system injury in rats. Carcinogenesis, Teratogenesis & Mutagenesis 2017; 29(5):346-351. doi:10.3969/j.issn.1004-616x.2017.05.005.

[20] Liu T, Zhang P, Ling Y, Hu G, Gu J, Yang H, et al. Protective Effect of Colla corii asini against Lung Injuries Induced by Intratracheal Instillation of Artificial Fine Particles in Rats. Int J Mol Sci 2018; 20(1):55. doi:10.3390/ijms20010055, PMID:30583600.

[21] Lugg ST, Scott A, Parekh D, Naidu B, Thickett DR. Cigarette smoke exposure and alveolar macrophages: mechanisms for lung disease. Thorax 2022; 77(1):94-101. doi:10.1136/thoraxjnl-2020-216296, PMID:33986144.

[22] Han J, Hou J, Liu Y, Liu P, Zhao T, Wang X. Using Network Pharmacology to Explore the Mechanism of Panax notoginseng in the Treatment of Myocardial Fibrosis. J Diabetes Res 2022; 2022:8895950. doi:10.1155/2022/8895950, PMID:35372585.

[23] Zhang Y, Li Z, Wei J, Kong L, Song M, Zhang Y, et al. Network pharmacology and molecular docking reveal the mechanism of Angelica dahurica against Osteosarcoma. Medicine (Baltimore) 2022; 101(44):e31055. doi:10.1097/MD.0000000000031055, PMID:36343039.

[24] Wang C, Liu X, Guo S. Network pharmacology-based strategy to investigate the effect and mechanism of α-solanine against glioma. BMC Complement Med Ther 2023; 23(1):371. doi:10.1186/s12906- 023-04215-1, PMID:37865727.

[25] Wang D, Ru W, Xu Y, Zhang J, He X, Fan G, et al. Chemical constituents and bioactivities of Colla corii asini. Drug Discov Ther 2014; 8(5):201-207. doi:10.5582/ddt.2014.01038, PMID:25382554.

[26] Nazakaiti·Ainiwar, Hu G, Zhang TT, Song MY, Zhao HM, Jin HT, et al. Effects of Colla corii asini on lung function and pathological injury in rats with chronic obstructive pulmonary disease. Basic & Clinical Medicine 2021; 41(7):970-974. doi:10.16352/j.issn.1001-6325.2021.07.004.

[27] Barnes PJ. Inflammatory mechanisms in patients with chronic obstructive pulmonary disease. J Allergy Clin Immunol 2016; 138(1):16-27. doi:10.1016/j.jaci.2016.05.011, PMID:27373322.

[28] Chen J, Wang T, Li X, Gao L, Wang K, Cheng M, et al. DNA of neutrophil extracellular traps promote NF-κB-dependent autoimmunity via cGAS/TLR9 in chronic obstructive pulmonary disease. Signal Transduct Target Ther 2024; 9(1):163. doi:10.1038/s41392-024-01881-6, PMID:38880789.

[29] Hussain AR, Ahmed SO, Ahmed M, Khan OS, Al Abdulmohsen S, Platanias LC, et al. Cross-talk between NFkB and the PI3-kinase/AKT pathway can be targeted in primary effusion lymphoma (PEL) cell lines for efficient apoptosis. PLoS One 2012; 7(6):e39945. doi:10.1371/ journal.pone.0039945, PMID:22768179.

[30] Bozinovski S, Vlahos R, Hansen M, Liu K, Anderson GP. Akt in the pathogenesis of COPD. Int J Chron Obstruct Pulmon Dis 2006; 1(1):31-38. doi:10.2147/copd.2006.1.1.31, PMID:18046900.

[31] Wang C, Zhou J, Wang J, Li S, Fukunaga A, Yodoi J, et al. Progress in the mechanism and targeted drug therapy for COPD. Signal Transduct Target Ther 2020; 5(1):248. doi:10.1038/s41392-020-00345-x, PMID:33110061.

[32] Li D, Xue XM, Cai HY, Zhang Y, Meng LH, Qiao WX, et al. Study on the mechanism of autophagy-related genes in the treatment of chronic obstructive pulmonary disease with Xuanfei Pingchuan capsule based on transcriptome sequencing. Lishizhen Medicine and Materia Medica Research 2024; 35(12):2891-2897. doi:10.3969/j.issn.1008-0805.2024.12.33.

[33] Chinese Medical Association, et al. Chinese Medical Association Publishing House, Chinese Society of General Practice, Chronic Obstructive Pulmonary Disease Study Group of Chinese Thoracic Society, Editorial Board of Chinese Journal of General Practitioners of Chinese Medical Association, Expert Group of Guidelines for Primary Care of Respiratory System Disease, Chinese guideline for management of chronic obstructive pulmonary disease in primary care (2024). Chinese. Journal of General Practice 2024; 23(6):578-602. doi:10.3760/cma.j.cn114798-20240326-00174.

[34] Guo P, Li R, Piao TH, Wang CL, Wu XL, Cai HY. Pathological Mechanism and Targeted Drugs of COPD. Int J Chron Obstruct Pulmon Dis 2022; 17:1565-1575. doi:10.2147/COPD.S366126, PMID:35855746.